List of partners

The following companies and organisations will join the 31st ECNP Congress.

In alphabetical order: 

ABP - Brazilian Psychiatric Association
Stand number: 16
The Brazilian Psychiatric Association (ABP) is a non-profit organisation which acts in defence of psychiatric labour rights and development. ABP organises the Brazilian Congress of Psychiatry (CBP), the third major event in the world. ABP publishes the premier scientific journal in the medical community of Latin America, the Revista Brasileira de Psiquiatria. www.abp.org.br

  ABP 

Allergan Plc
Expert science exchange: CE.02
Allergan plc, headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
www.allergan.com

  Allergan 

ANGELINI           
Stand number: 9
Satellite symposia: C.09 & C.12
Angelini is a privately held international pharmaceutical company. Founded in Italy in 1919, it has branches in 20 countries and employs 6,000 people. Angelini’s research is focused on nervous system diseases and disorders, infectious diseases, pain and inflammation. www.angelini.it

   Angelini

BIOPAC Systems, Inc.
Stand number: 20
BIOPAC lets you measure physiology anywhere with innovative, compatible solutions that can be used by anyone for meaningful discovery. We make high-quality scientific tools for physiology measurement and interpretation with superior compatibility and world-class support. Empowering cutting edge tools that inspire discovery in ambulatory, MRI, lab, and real-world. www.biopac.com

   Biopac

C2Care
Stand number: 21
Virtual reality in the service of health C2care designs therapeutic software based on virtual reality for all healthcare professionals. The main goal of this new comprehensive therapeutic tool is to treat patients with depression, phobias, addictions, eating disorders and balance disorders through immersion brought by virtual reality. www.c2.care

  C2Care 
CINP - The International College of Neuropsychopharmacology
Stand number: 24
CINP (Collegium Internationale Neuro-Psychopharmacologicum) is the world’s global psychopharmacology organisation. Its mission is to encourage and promote international scientific study, teaching and the application of neuropsychopharmacology. It provides advice and consultation for the evaluation of all aspects of neuropsychiatric drugs, including biochemistry, pharmacology, safety and therapeutic efficacy. www.cinp.org
  CINP 

EBC - European Brain Council
Stand number: 12
The European Brain Council (EBC) is a non-profit organisation gathering patient associations, major brain-related societies and companies. Its mission is to promote brain research in order to improve the quality of life of those living with brain disorders in Europe. 165 million Europeans have a brain disorder, costing more than EUR 800 billion annually. www.braincouncil.eu

  European Brain Council 

EPA - European Psychiatric Association
Stand number: 15
With active individual members in as many as 88 countries and 43 National Psychiatric Association Members who represent more than 80,000 European psychiatrists, the European Psychiatric Association is the main association representing psychiatry in Europe. The EPA’s activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development. www.europsy.net

   EPA

EUFAMI
Stand number: 14
EUFAMI is an international NGO based in Belgium committed to improving the care for and welfare of people with mental illness. Our mission is to represent at the European level all family members of persons that are affected by mental illness and to protect their rights and interests. www.eufami.org

  EUFAMI 

GAMIAN-Europe
Stand number: 13
GAMIAN-Europe, a patient-driven pan-European organisation, representing the interests of persons affected by mental health illness and advocates for their rights. GAMIAN-Europe was established in 1998 as a representative coalition of patient organisations putting the patient at the centre of all issues of the EU healthcare debate. www.gamian.eu

   GAMIAN-EUROPE

Gedeon Richter Plc.
Stand number: 8
Satellite symposium: C.10
Headquartered in Hungary, Gedeon Richter is an innovation-driven specialty pharmaceutical company. It has manufacturing subsidiaries in five countries and markets its products in one hundred countries. Its latest achievement in R&D is the original antipsychotic compound, cariprazine, already marketed in the US for bipolar mania and schizophrenia treatment and received marketing authorization in the EU for the treatment of schizophrenia. www.richter.hu

  gedeon-richter 
Genomind
Stand number: 19
Genomind is a unique personalised medicine platform that brings innovation to healthcare around the world. Genomind, comprised of pioneering scientists and thought leaders in brain health and genetics, delivers actionable insights to clinicians, healthcare partners and individuals in order to improve the quality of human life. Genomind is a CLIA certified and CAP accredited laboratory. www.genomind.com 
  Genomind 

Global Medical Education
Satellite symposium: C.08
Expert science exchange: CE.01 and CE.02

Global Medical Education (GME), based in New York, is a medical education company, focusing primarily on psychiatry, that offers free, timely, unbiased, evidence-based information from the world’s leading experts to clinicians around the world through a variety of formats including live meetings and online media. www.gmeded.com

  GME 

H. Lundbeck A/S
Stand number: 4
Satellite symposia: C.01, C.02, C.04, C.05 and C.13
Expert science exchange:
  CE.06 and CE.07
Lundbeck is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.
An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind
Connect with us on Twitter at @Lundbeck and via our LinkedIn company page.
www.lundbeck.com

   Lundbeck
Karger Publishers
Karger Publishers in Basel, Switzerland, is a globally active medical and scientific publishing company. Independent and family-run in the fourth generation by Vice Chairwoman & Publisher Gabriella Karger and Chairman Thomas Karger, the company is dedicated to serving the information needs of the scientific community with publications of high-quality content, covering all fields of medical science. Karger offers an extremely comprehensive portfolio in psychiatry and psychology, which will be of interest to both researchers in basic and clinical science and to practicing clinicians. www.karger.com/psychiatry
  Karger 

JAMA Network
Stand number: 17
Building on a tradition of editorial excellence, the JAMA Network brings JAMA together with eleven specialty journals to offer enhanced access to the research, reviews, and opinions shaping the future of medicine. JAMA Network Open, a new open access, general medical journal, launched in 2018. www.jamanetwork.com

   Jama Network

Janssen Pharmaceutica NV
Stand number: 1
Satellite symposium: C.03 and C.06

At Janssen, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We collaborate with the world for the health of everyone in it.
Follow us at www.twitter.com/janssenEMEA
www.janssen.com

  Janssen

Massachusetts General Hospital
Stand number: 18
The MGH Clinical Trial Network and Institute is setting new standards in psychiatric clinical research by implementing trial methodologies and strategies designed to reduce placebo response. Our proprietary SAFER interview, innovative rater training, SPCD study design, and access to KOLs enable us to offer sponsors an unsurpassed track record in CNS studies. www.mgh-Ctni.org

  Massachusetts General Hospital
 

Lundbeck Institute
Stand number: 4
Our mission is to develop and cascade unbiased, evidence-based medical education in psychiatry and neurology from leading experts to health care professionals and create a forum to facilitate knowledge-sharing. Since 1997 we have been committed to providing expert, international, interactive seminars, thereby building a valued legacy in medical education. www.lundbeck.com

   Lundbeck Institute
Magventure
Stand number: 25
MagVenture's mission is to be the most dynamic and innovative supplier of transcranial magnetic stimulation solutions. Many "first mover" features and improvements have been developed over the years in response to ideas and requests from our customers. www.magventure.com
  Magventure 

NbN - Neuroscience-based Nomenclature
Stand number: 10
Nomenclature session: NS.01 

The Neuroscience-based Nomenclature (NbN) is an ECNP-led international collaboration established to align the nomenclature of psychotropic drugs with the neuroscience underlying them. The new nomenclature encompasses all medications with CNS indications and is now available to clinicians for free download on the iOS App Store and the Google Play Store. The NbN comes in both general and child and adolescent editions. www.nbn2.com

 
 

Otsuka Pharmaceutical Europe Ltd
Stand number: 3
Satellite symposia: C.01
Otsuka Pharmaceutical Development and Commercialization, Inc
Satellite symposia C.13
Expert science exchange: CE.07

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’ Otsuka’s 45,000 employees ensure that patients have access to innovative products and medical devices in our therapy areas of central nervous system disorders, endocrinology, nephrology, gastroenterology and oncology.
www.otsuka-europe.com
www.otsuka-us.com

   Otsuka
P1vital Products Ltd
Stand number: 23
At P1vital Products Ltd (PPL), we build on scientific research and collaborate with experts in academia and industry to develop evidence-based digital health innovations that are high quality, cost-effective, reliable and easy to use in both clinical research and healthcare settings to bring benefit to patients’ lives. www.p1vitalproducts.com
  P1vital Products Ltd 

Pfizer Inc.
Expert science exchange: CE.03
At Pfizer, we apply science and our global resources to bring therapies that extend and significantly improve people's lives. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. www.pfizer.com

  Pfizer 

RECORDATI S.p.A
Stand number: 8
Satellite symposium: C.10
Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Recordati is committed to the research and development of new specialties within cardiology, psychiatric and urogenital therapeutic area and of treatments for rare diseases. www.recordati.com

   Recordati

Sage Therapeutics
Stand number: 22
Sage Therapeutics is committed discovering and developing life-altering therapies to treat central nervous system (CNS) disorders, and we are dedicated in our pursuit to deliver new medicines with the goal of making life better for patients and their families. www.sagerx.com

  SAGE 

Saladax Biomedical
Expert science exchange: CE.01

Saladax develops rapid blood tests to measure levels of antipsychotic drug in a patient. These tests will enable psychiatrists to better assess adherence and better adjust dosing. The Saladax MyCare Psychiatry line will provide antipsychotic drug levels for greater insight into patient adherence and possible treatment failures. Saladax believes that truly personalised medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2003 certified.
www.MyCareTests.com
www.saladax.com

  Saladax 
Schwabe Group
Stand number: 2
Satellite symposium: C.11

The Schwabe Group comprises several different affiliated companies in the pharmaceutical and health industry. All of the companies within the Group focus on plants as the basis for developing pharmaceuticals and health products. The original form of the Group’s parent company, which is now Dr. Willmar Schwabe GmbH & Co. KG, is one of the oldest pharmaceutical manufacturers in Europe and has a company history dating back over 150 years. www.schwabe-group.com 
   Schwabe

SERVIER
Stand number: 7
Satellite symposium: C.07
Servier is an international independent pharmaceutical company governed by a non-profit foundation. Neuropsychiatry is one of the fifth therapeutic areas where research and development of innovative therapeutic solutions for patients are concentrated. Agomelatine was approved in 2009 for the treatment of depression. Multiple sclerosis and autism spectrum disorders are also areas of interest for Servier. www.servier.com

   SERVIER

Shire
Satellite symposium: C.08
Expert science exchange: CE.04 & CE.05 
With more than 20 years of experience, Shire is a global leader in ADHD education and treatment innovation. We are committed to raising awareness of this impairing psychiatric disorder through engagement with physicians, patients and caregivers. Shire enable people with life-altering conditions in specialty and rare diseases to live their lives to the fullest. We work tirelessly to develop breakthrough medicines that have a meaningful impact on these patients and all who support them on their journey. Our diverse capabilities enable us to reach patients in over 100 countries across therapeutic areas such as neuroscience, rare diseases, haematology and immunology. www.shire.com

  Shire

Sumitomo Dainippon Pharma Co., Ltd.
Satellite symposium: C.09
Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US. Sumitomo Dainippon Pharma Co., Ltd. is among the top-ten listed pharmaceutical companies in Japan operating globally. www.ds-pharma.com

  Sumitomo

Sunovion Pharmaceuticals Europe
Stand number: 9
Satellite symposium: C.09

Sunovion Pharmaceuticals Europe, headquartered in London, is a wholly owned subsidiary of Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US. www.sunovion.eu.

   Sunovion

Wisepress Medical Bookshop
Stand number: 5
Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of the ECNP Congress available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks. www.wisepress.com